Rule 2.9 Announcement
Updated : 16:06
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
21 March 2018
Vernalis plc ("Vernalis", the "Company", or the "Group")
Rule 2.9 Announcement
In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, Vernalis confirms that as at the date of this announcement, it has 526,819,624 ordinary shares of one pence each in issue and admitted to trading on the AIM market of the London Stock Exchange. There are no shares held in treasury. Accordingly, the total number of voting rights in Vernalis is 526,819,624. The International Securities Identification Number ("ISIN") for the Company's ordinary shares is GB00B3Y5L754.
Vernalis has a Sponsored Level 1 American Depositary Receipt ("ADR") facility in the United States with ISIN US92431M2061, with each ADR representing two Vernalis ordinary shares of one pence each in the issued share capital of the Company. The Company's ADRs are traded on the US over-the-counter market under the symbol 'VNLPY'.
Enquiries:
Vernalis plc: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Canaccord plc (Nominated Adviser and Joint Broker): | +44 (0) 20 7523 8000 |
Henry Fitzgerald-O'Connor Emma Gabriel
| |
Shore Capital (Joint Broker): | +44 (0)20 7408 4090 |
Mark Percy Toby Gibbs
| |
FTI Consulting (Financial Communications): | +44 (0) 20 3727 1000 |
Ben Atwell Simon Conway Stephanie Cuthbert
| |
Evercore (Financial Adviser): | +44 (0) 20 7653 6000 |
Julian Oakley Alan Beirne
|
Notes to Editors
Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra® XR targeting the US prescription cough-cold market; Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
This information is provided by RNS